(RxWiki News) The US Food and Drug Administration (FDA) has approved five medications in the last month.
The FDA approved these medications to treat various conditions, ranging from a rare blood disorder to cystic fibrosis.
Starting things off, Adakveo (crizanlizumab-tmca) was approved to treat a common complication of sickle cell disease, which is an inherited blood disorder. This medication is available as an injection to be administered into the vein. The FDA granted this approval to Novartis.
Another recent approval was for Fetroja (cefiderocol). It’s an antibiotic approved to treat complicated urinary tract infections in adults who have limited treatment options. This medication, from Shionogi & Co., Ltd., is available as an injection to be administered into the vein.
Brukinsa (zanubrutinib) was approved to treat mantle cell lymphoma, a type of non-Hodgkin’s lymphoma, in adults. It is available in capsule form. This medication’s approval was granted to BeiGene USA Inc.
Another medication that was approved recently is Reblozyl (luspatercept–aamt). The FDA approved it to treat anemia (lack of red blood cells) (beta thalassemia) in adults who need regular red blood cell transfusions. This medication is available as an injection to be administered under the fatty layer of the skin. This medication’s approval was granted to Celgene Corporation.
Trikafta (elexacaftor/ivacaftor/tezacaftor) was approved to treat those with the most common cystic fibrosis mutation. This medication is available in tablet form. Vertex Pharmaceuticals Incorporated was granted approval for this drug.
Speak with your health care provider if you have any questions about any of these new drug approvals.
Written by Anyssa Garza, PharmD, BCMAS